0001193125-26-177400.txt : 20260424 0001193125-26-177400.hdr.sgml : 20260424 20260424163010 ACCESSION NUMBER: 0001193125-26-177400 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260422 FILED AS OF DATE: 20260424 DATE AS OF CHANGE: 20260424 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chadwick Jeremy G CENTRAL INDEX KEY: 0001388406 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 26894743 MAIL ADDRESS: STREET 1: C/O KYMERA THERAPEUTICS, INC. STREET 2: 200 ARSENAL YARDS BLVD., SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 ownership.xml 4 X0609 4 2026-04-22 0001815442 Kymera Therapeutics, Inc. KYMR 0001388406 Chadwick Jeremy G false C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 false true false false Chief Operating Officer true Common Stock 2026-04-22 4 M false 100 30.17 A 61302 D Common Stock 2026-04-22 4 M false 200 43.5 A 61502 D Common Stock 2026-04-22 4 S false 300 90 D 61202 D Stock Option (Right to Buy) 30.17 2026-04-22 4 M false 100 0 D 2035-03-02 Common Stock 100 45434 D Stock Option (Right to Buy) 43.50 2026-04-22 4 M false 200 0 D 2034-02-28 Common Stock 200 58263 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. /s/ Bruce Jacobs, as Attorney-in-Fact 2026-04-24